Patents by Inventor Timothy Cardozo
Timothy Cardozo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210340188Abstract: Embodiments of recombinant HIV-1 gp120 proteins that contain a V1 deletion are disclosed. Also provided are gp140, gp145, and gp160 proteins containing the V1 deletion, as well as HIV-1 Env ectodomain trimers containing protomers containing the V1 deletion. Nucleic acid molecules encoding these proteins are also provided. In several embodiments, the disclosed recombinant HIV-1 proteins and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject, for example, to treat or prevent an HIV-1 infection in the subject.Type: ApplicationFiled: October 21, 2019Publication date: November 4, 2021Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, New York UniversityInventors: Genoveffa Franchini, Timothy Cardozo, Manuel Becerra-Flores, Isabela Silva de Castro, Giacomo Gorini, Massimiliano Bissa
-
Patent number: 9969782Abstract: The present invention relates to an isolated immunogenic peptide chimera comprising a first peptide moiety comprising the amino acid sequence of SEQ ID NO: 1, or at least a contiguous 5 amino acid fragment thereof, a second peptide moiety comprising the amino acid sequence of SEQ ID NO: 2, or at least a contiguous 5 amino acid fragment thereof, and a linker joining the first and second peptide moieties, wherein the first peptide moiety is at the immunogenic peptide chimera's N-terminus and the second peptide moiety is at the immunogenic peptide chimera's C-terminus. Also disclosed is an immunogenic peptide including the amino acid sequence corresponding to SEQ ID NO: 6, or at least a contiguous 5 amino acid fragment thereof, having a length sufficient to form ?-hairpin structure.Type: GrantFiled: October 7, 2014Date of Patent: May 15, 2018Assignee: New York UniversityInventor: Timothy Cardozo
-
Publication number: 20170190764Abstract: The present invention relates to an isolated immunogenic peptide comprising a V2 loop fragment from HIV surface envelope glycoprotein gp120. This peptide binds specifically with antibodies in blood of patients vaccinated with a vaccine that has shown protection from HIV-1 infection, does not react with blood of matched patients who did not receive the vaccine, and can, therefore, elicit anti-HIV-1 antibodies which protect against HIV-1 infection. Other aspects of the present invention relate to an isolated immunogenic polypeptide comprising the peptide inserted into an immunogenic scaffold protein, a vaccine composition comprised of the immunogenic peptide and an immunologically or pharmaceutically acceptable vehicle or excipient as well as methods of inducing an immune response against HIV-1 and methods of detecting HIV-1.Type: ApplicationFiled: March 13, 2017Publication date: July 6, 2017Inventors: Timothy CARDOZO, Xiangpeng KONG, Susan ZOLLA-PAZNER
-
Patent number: 9611294Abstract: The present invention relates to an isolated immunogenic peptide comprising a V2 loop fragment from HIV surface envelope glycoprotein gp120. This peptide binds specifically with antibodies in blood of patients vaccinated with a vaccine that has shown protection from HIV-1 infection, does not react with blood of matched patients who did not receive the vaccine, and can, therefore, elicit anti-HIV-1 antibodies which protect against HIV-1 infection. Other aspects of the present invention relate to an isolated immunogenic polypeptide comprising the peptide inserted into an immunogenic scaffold protein, a vaccine composition comprised of the immunogenic peptide and an immunologically or pharmaceutically acceptable vehicle or excipient as well as methods of inducing an immune response against HIV-1 and methods of detecting HIV-1.Type: GrantFiled: September 12, 2012Date of Patent: April 4, 2017Assignee: New York UniversityInventors: Timothy Cardozo, Xiangpeng Kong, Susan Zolla-Pazner
-
Patent number: 9534020Abstract: The present invention is directed to a recombinant immunogenic polypeptide. The polypeptide includes a loop peptide inserted into an immunogenic scaffold protein. The loop polypeptide has an amino acid sequence which presents the 3074 mAb- or the 2219/2557 mAb-targeted epitope of the HIV gp120 protein and not other known epitopes of the HIV gp120 protein. When used as an immunogen, the polypeptide induces an antibody response which neutralizes heterologous HIV-1 viruses in a pattern similar to that observed for the 3074 mAb- or the 2219/2557 mAb-targeted epitope, respectively. Pharmaceutical compositions containing the immunogenic polypeptide as well as methods of making and using it are also disclosed.Type: GrantFiled: September 28, 2011Date of Patent: January 3, 2017Assignees: New York University, University of Massachusetts, Molsoft LLCInventors: Timothy Cardozo, Xiang-peng Kong, Susan Zolla-Pazner, Shan Lu, Shixia Wang, Maxim Totrov
-
Patent number: 9261497Abstract: The present invention relates to pharmaceutical compositions comprising a compound and a pharmaceutically acceptable carrier. The present invention is also directed to a method of treating cancer in a subject. Also disclosed are methods of inhibiting SCF-Skp2 activity and a method of identifying inhibitors of SCF-Skp2 activity.Type: GrantFiled: October 16, 2013Date of Patent: February 16, 2016Assignee: New York UniversityInventors: Timothy Cardozo, Michele Pagano, Lily Wu, Leslie I. Gold
-
Patent number: 9198891Abstract: The present invention relates to a method of identifying compounds useful in inhibiting protein kinase-like endoplasmic reticulum protein kinase (PERK). The method comprises providing a first model comprising PERK active domains, where the said active domains are selected from the group consisting of the peptide spanning from amino acid residue Asp144 to amino acid residue Ser191 of SEQ ID NO: 1 and a peptide comprising the amino acid residue at position 7 of SEQ ID NO: 1, providing one or more candidate compounds, evaluating contact between the candidate compounds and the first model to determine which of the one or more candidate compounds have an ability to bind to and/or fit in the first model, and identifying the compounds which, based on said evaluating, have the ability to bind to and/or fit in the first model as compounds potentially useful for inhibiting PERK.Type: GrantFiled: May 19, 2011Date of Patent: December 1, 2015Assignee: New York UniversityInventors: Timothy Cardozo, Hong Wang, David Ron
-
Publication number: 20150125476Abstract: The present invention relates to an isolated immunogenic peptide chimera comprising a first peptide moiety comprising the amino acid sequence of SEQ ID NO: 1, or at least a contiguous 5 amino acid fragment thereof, a second peptide moiety comprising the amino acid sequence of SEQ ID NO: 2, or at least a contiguous 5 amino acid fragment thereof, and a linker joining the first and second peptide moieties, wherein the first peptide moiety is at the immunogenic peptide chimera's N-terminus and the second peptide moiety is at the immunogenic peptide chimera's C-terminus. Also disclosed is an immunogenic peptide including the amino acid sequence corresponding to SEQ ID NO: 6, or at least a contiguous 5 amino acid fragment thereof, having a length sufficient to form ?-hairpin structure.Type: ApplicationFiled: October 7, 2014Publication date: May 7, 2015Applicant: NEW YORK UNIVERSITYInventor: Timothy CARDOZO
-
Publication number: 20140142120Abstract: The present invention relates to pharmaceutical compositions comprising a compound and a pharmaceutically acceptable carrier. The present invention is also directed to a method of treating cancer in a subject. Also disclosed are methods of inhibiting SCF-Skp2 activity and a method of identifying inhibitors of SCF-Skp2 activity.Type: ApplicationFiled: October 16, 2013Publication date: May 22, 2014Applicant: NEW YORK UNIVERSITYInventors: Timothy Cardozo, Michele Pagano, Lily Wu, Leslie I. Gold
-
Publication number: 20130287804Abstract: The present invention is directed to a recombinant immunogenic polypeptide. The polypeptide includes a loop peptide inserted into an immunogenic scaffold protein. The loop polypeptide has an amino acid sequence which presents the 3074 mAb- or the 2219/2557 mAb-targeted epitope of the HIV gp120 protein and not other known epitopes of the HIV gp120 protein. When used as an immunogen, the polypeptide induces an antibody response which neutralizes heterologous HIV-1 viruses in a pattern similar to that observed for the 3074 mAb- or the 2219/2557 mAb-targeted epitope, respectively. Pharmaceutical compositions containing the immunogenic polypeptide as well as methods of making and using it are also disclosed.Type: ApplicationFiled: September 28, 2011Publication date: October 31, 2013Applicants: NEW YORK UNIVERSITY, UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY, UNIVERSITY OF MASSACHUSETTS, MOLSOFT LLCInventors: Timothy Cardozo, Xian-peng Kong, Susan Zolla-Pazner, Abraham Pinter, Chavdar Krachmarov, Shan Lu, Shixia Wang, Maxim Totrov
-
Publication number: 20130071424Abstract: The present invention relates to an isolated immunogenic peptide comprising a V2 loop fragment from HIV surface envelope glycoprotein gp120. This peptide binds specifically with antibodies in blood of patients vaccinated with a vaccine that has shown protection from HIV-1 infection, does not react with blood of matched patients who did not receive the vaccine, and can, therefore, elicit anti-HIV-1 antibodies which protect against HIV-1 infection. Other aspects of the present invention relate to an isolated immunogenic polypeptide comprising the peptide inserted into an immunogenic scaffold protein, a vaccine composition comprised of the immunogenic peptide and an immunologically or pharmaceutically acceptable vehicle or excipient as well as methods of inducing an immune response against HIV-1 and methods of detecting HIV-1.Type: ApplicationFiled: September 12, 2012Publication date: March 21, 2013Applicant: NEW YORK UNIVERSITYInventors: Timothy CARDOZO, Xiangpeng KONG, Susan ZOLLA-PAZNER
-
Publication number: 20110288083Abstract: The present invention relates to a method of identifying compounds useful in inhibiting protein kinase-like endoplasmic reticulum protein kinase (PERK). The method comprises providing a first model comprising PERK active domains, where the said active domains are selected from the group consisting of the peptide spanning from amino acid residue Asp144 to amino acid residue Ser191 of SEQ ID NO: 1 and a peptide comprising the amino acid residue at position 7 of SEQ ID NO: 1, providing one or more candidate compounds, evaluating contact between the candidate compounds and the first model to determine which of the one or more candidate compounds have an ability to bind to and/or fit in the first model, and identifying the compounds which, based on said evaluating, have the ability to bind to and/or fit in the first model as compounds potentially useful for inhibiting PERK.Type: ApplicationFiled: May 19, 2011Publication date: November 24, 2011Applicant: NEW YORK UNIVERSITYInventors: Timothy CARDOZO, Hong WANG, David Ron
-
Patent number: 7638319Abstract: Newly discovered structural characteristic of the gp120 V3 loop have resulted in a “rule” or algorithm, that is used in a method for determining whether a subject is infected with HIV-1 virus that expresses selectivity for CXCR4 or CCR5 chemokine receptors. A positively charged surface patch defined by V3 loop residues 11 and 24 or 25 at the base of the ?-strands in the V3 loop and the homologous ?2-?3 chemokine hairpin is responsible for CXCR4 receptor selection. Thus a method for detecting the presence of HIV-1 virus that is selective for X4-co-receptors in a subject infected with HIV-1 or suspected of being infected, from the amino acid sequence of at least a part of the HIV-1 gp120 V3 region peptide that includes residues 11, 24 and 25, or from the nucleotide sequence of a nucleic acid encoding said V3 region peptide, is disclosed.Type: GrantFiled: March 7, 2006Date of Patent: December 29, 2009Assignee: New York UniversityInventors: Timothy Cardozo, Susan Zolla-Pazner
-
Publication number: 20070072200Abstract: Newly discovered structural characteristic of the gp120 V3 loop have resulted in a “rule” or algorithm, that is used in a method for determining whether a subject is infected with HIV-1 virus that expresses selectivity for CXCR4 or CCR5 chemokine receptors. A positively charged surface patch defined by V3 loop residues 11 and 24 or 25 at the base of the ?-strands in the V3 loop and the homologous ?2-?3 chemokine hairpin is responsible for CXCR4 receptor selection. Thus a method for detecting the presence of HIV-1 virus that is selective for X4-co-receptors in a subject infected with HIV-1 or suspected of being infected, from the amino acid sequence of at least a part of the HIV-1 gp120 V3 region peptide that includes residues 11, 24 and 25, or from the nucleotide sequence of a nucleic acid encoding said V3 region peptide, is disclosed.Type: ApplicationFiled: March 7, 2006Publication date: March 29, 2007Applicant: New York UniversityInventors: Timothy Cardozo, Susan Zolla-Pazner
-
Publication number: 20050085438Abstract: The present invention relates to the treatment of inflammatory skin conditions, including psoriasis, with a prodrug of 5-fluorouracil. The invention relates to methods for treatment of psoriasis with capecitabine, an oral prodrug of 5-fluorouracil.Type: ApplicationFiled: October 17, 2003Publication date: April 21, 2005Inventors: Timothy Cardozo, John Pui